ChromaDex Looks To Pharma Model For Commercializing Supplement Research
This article was originally published in The Tan Sheet
Executive Summary
Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.
You may also be interested in...
In Brief
Ramirez appointed FTC chair; budget sequester slows FDA travel, training; ChromaDex divests BluScience brand; Omega Protein buys whey firm; Vitamin Shoppe absorbs integration costs; Vitacost trims net loss in Q4; chemical regulation champion Lautenberg to retire; USANA expands in China.
In Brief
Novartis begins OTC recovery with Excedrin; Abbott Nutrition up double digits in Q2; trade groups discuss supplement GMPs with Sen. Durbin; ChromaDex licenses patents for nicotinamide riboside; Nature Made supplements alleged to contain pork by-products; more news In Brief.
People In Brief
Jakobsen next in line as Mead Johnson CEO; Blake takes over Bayer U.S. from Babe; Himmel ends brief tenure as ChromaDex CEO; Capitol Hill veteran O’Donnell joins NACDS; Merz makes Hartman derma VP; USANA strengthens scientist roster; more People In Brief.